PRINCETON, N.J., June 16, 2020 /PRNewswire/ — Quartesian, a multinational clinical research organization (CRO) serving the biopharmaceutical and medical device industries, today announced a new partnership with Amyndas Pharmaceuticals for their Phase 2 clinical study evaluating the efficacy of AMY-101 in COVID-19 patients with acute respiratory distress syndrome (ARDS). ARDS, a life-threatening type of lung failure, is a common complication in severe COVID-19 patients.
Amyndas Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of the most advanced C3 complement therapeutics. AMY-101 is a new-generation potent complement inhibitor. The trial is designed to study whether AMY-101 can halt the broad thromboinflammatory response associated with COVID-19. For more information about the Phase 2 AMY-101_SAVE study (ClinicalTrials.gov Identifier: NCT04395456), please visit https://www.amyndas.com/covid-19/.
Quartesian is a premier resource for sponsors and CROs who need to get quality results — faster — at a lower cost. They have delivered thousands of CDISC SDTM and ADaM datasets for more than 200 pharma, biotech, medical device, and CRO clients. Quartesian will support Amyndas with EDC technology and data management, biostats, pharmacovigilance, and medical writing services to get this study up and running quickly to help people struggling with COVID-19 in the earliest possible time frame.
“Quartesian tremendously values the relationship we have with Amyndas and we look forward to collaborating on this special trial,” said Ben Jackson, president and CEO of Quartesian. “This study will help to more thoroughly understand the role of C3 complement inhibitors for the treatment of COVID-19 symptoms and it is an important step in the clinical development of AMY-101. We are grateful to be able to contribute to the management of this global health crisis.”
Quartesian is now part of Veranex.
Veranex is the only truly comprehensive, global, tech-enabled service provider dedicated to the medical technology industry. Offering expert guidance from concept through to commercialization and across the development continuum, Veranex enables accelerated speed to market, controlled development costs, development risk mitigation, and accelerated market viability assessment. At every stage, Veranex customers realize efficiencies in cost and time while its integrated and comprehensive solutions unify the entire development process.
About Amyndas Pharmaceuticals
Amyndas Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing the most advanced complement therapies to treat inflammatory disorders, in areas of unmet medical need for which patients need better and safer therapies. Amyndas has a robust R&D program with the strongest and most diversified pipeline of C3 complement inhibitors in the field. For additional information about AMY-101 and Amyndas Pharmaceuticals, please visit www.amyndas.com.